Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $223000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 16.48% year-over-year to $223000.0, compared with a TTM value of $1.3 million through Sep 2025, up 126.84%, and an annual FY2024 reading of $796000.0, up 89.98% over the prior year.
  • Depreciation & Amortization (CF) was $223000.0 for Q3 2025 at X4 Pharmaceuticals, down from $355000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $476000.0 in Q1 2025 and bottomed at $62000.0 in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $172684.2, with a median of $132000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 51.18% in 2024, then soared 667.74% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $132000.0 in 2021, then dropped by 6.06% to $124000.0 in 2022, then crashed by 50.0% to $62000.0 in 2023, then surged by 340.32% to $273000.0 in 2024, then fell by 18.32% to $223000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for XFOR at $223000.0 in Q3 2025, $355000.0 in Q2 2025, and $476000.0 in Q1 2025.